Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.
Breast Neoplasm
DRUG: Aminoflavone Prodrug
Clinical Benefit Response, 6 months
Progression Free Survival, 6 monhts
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.